_______________________________________________________________________________________________________________
the cell and gene therapy market. The company began as a business focused on innovation and platform development. Today, OXB operates as a viral vector CDMO across the UK, France, and the US, supporting lentiviral, AAV, adenoviral, measles, MVA, and other vector programs from development to commercial supply.
OXB did not make this transition through one big move. Instead, the company grew through acquisitions and capability expansion, transforming from a specialist lentiviral vector provider into a full-service viral vector CDMO.
OXB’ s first real test came when demand outpaced its capacity. The company had planned to expand in Bedford, Massachusetts, and had started engineering work. Then, an opportunity arose to acquire a former National Resilience facility in Durham, North Carolina. That prompted OXB to reconsider how quickly, and in what way, it could add capacity.“ We looked at the pros and cons of buying versus building. Acquiring the facility was faster than continuing the expansion in Bedford, and we weren’ t just buying a
shell. We were bringing in an experienced team that was already operating there.” The acquisition brought manufacturing suites, regulatory history, and operational experience into the business in a single move.“ It has really been a game changer,” adds Sébastien.
Durham’ s significance goes beyond the facility. It is visible proof of OXB’ s new direction. Customers now see a bigger manufacturing footprint, broader capabilities, and a growing focus on late-stage and commercial work.
OXB made the acquisition to meet existing demand, not just future potential.“ We weren’ t expanding capacity in anticipation of new clients. We had already secured new clients, which led us to accelerate our US expansion and bring additional capacity online much more quickly.” That distinction matters. Instead of building capacity for possible growth, OXB responded to growth that was already knocking at its door.
OXB’ s expansion story does not stop in North Carolina. Across Europe, OXB has followed a similar playbook, building
120